MMSI vs RDNT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MMSI presents a dichotomy between strong fundamental growth and poor market sentiment. While the Piotroski F-Score of 4/9 indicates stable but not strong financial health, the company boasts an exceptional track record of earnings beats over 25 quarters and strong YoY earnings growth of 38.8%. However, the stock is currently trading at $70.54, which is a premium to its Intrinsic Value ($62.83) and significantly above its Graham Number ($35.75). Bearish insider activity and a 0/100 technical trend offset the bullish analyst target of $101.18.
RDNT exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. While revenue growth remains positive at 14.8%, the company is struggling with negative profit margins (-0.91%) and a catastrophic collapse in year-over-year EPS growth (-104.5%). There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish reality of insider selling and negative earnings surprises. The valuation is aggressive, with a forward P/E of 58.82 that is not supported by current profitability.
Compare Another Pair
Related Comparisons
MMSI vs RDNT: Head-to-Head Comparison
This page compares Merit Medical Systems, Inc. (MMSI) and RadNet, Inc. (RDNT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.